Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab

Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab

Class 1 and 2 monoclonal antibodies inhibit SARS-CoV-2 entry by blocking the interaction of the viral receptor-binding domain with angiotensin-converting enzyme 2 (ACE2), while class 3 antibodies target a highly conserved epitope outside the ACE2 binding site. We aimed to investigate the plasticity...

Full description

Bibliographic Details
Main Authors: Clara Luzia Magnus, Andreas Hiergeist, Philipp Schuster, Anette Rohrhofer, Jan Medenbach, André Gessner, David Peterhoff, Barbara Schmidt
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
receptor-binding domain
monoclonal antibody
sotrovimab
immune escape
entry
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.966236/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.966236/full

Similar Items